Document is current
Any future updates will be listed below
-
Authors
Aydogan, Gökhan https://orcid.org/0000-0003-2187-7912
Daviet, Remi https://orcid.org/0000-0003-0838-3619
Karlsson Linnér, Richard https://orcid.org/0000-0001-7839-2858
Hare, Todd A. https://orcid.org/0000-0002-0260-2772
Kable, Joseph W. https://orcid.org/0000-0001-6495-9040
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Wetherill, Reagan R. https://orcid.org/0000-0002-1991-6292
Ruff, Christian C. https://orcid.org/0000-0002-3964-2364
Koellinger, Philipp D. https://orcid.org/0000-0001-7413-0412
,
Nave, Gideon https://orcid.org/0000-0001-6251-5630
- License Information
-
More Information
Article History
Received: 10 December 2019
Accepted: 26 November 2020
First Online: 28 January 2021
Competing interests
: H.R.K. is a member of an advisory board for Dicerna Pharmaceuticals; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was sponsored in the past three years by AbbVie, Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka and Pfizer; and is named as an inventor on PCT patent application no. 15/878,640, entitled ‘Genotype-guided dosing of opioid agonists’ and filed 24 January 2018. All other authors declare no competing interests.
